

NOV 25 2003

K032537

**Special 510(k) Notification  
MicrO2+ VA2 Modifications**

---

**510(k) SUMMARY**  
as required per 807.92(c)

Submitters Name, Address:

Draeger Medical Systems, Inc.  
Danvers, MA 01923  
Tel: (978) 907-7500  
Fax: (978) 750-6879  
Official Correspondent: Connie Hertel, Director  
Quality Assurance & Regulatory Affairs  
Contact person for this submission: Penelope H. Greco  
Date submission was prepared: November 24, 2003

Trade Name, Common Name and Classification Name:

A. Trade Name:

Draeger MicrO2+

B. Common Name, Classification Name, Class and Regulation Number:

<u>Common Name</u>	<u>Product Code</u>	<u>Class</u>	<u>Regulation Number</u>
Oximeter	74 DQA	II	870.2700
Ear Oximeter	74 DPZ	II	870.2710

Legally Marketed Device Identification:

MICRO2+, 510(k) K030640, K012770  
Masimo SET Radical Pulse Oximeter and LNOP Series Sensors, K013792

Description of Modification:

The release of software version VA2 includes a re-labeling of the MicrO2+ and the recognition of Masimo LNOP sensors. The modifications implemented with the release of software version VA2 have not altered the basic fundamental technology of the MicrO2+. Testing with VA2 software indicates no new issues relative to safety and efficacy.

---

COMPANY CONFIDENTIAL

**Draeger Medical Systems, Inc.**

16 Electronics Avenue  
Danvers, MA 01923

Tel: (978) 907-7500  
Fax (978) 750-6879

**Special 510(k) Notification**  
**MicrO2+ VA2 Modifications**

---

Intended Use:

The MICR02+ is intended for the continuous, non-invasive monitoring of functional oxygen saturation of arterial hemoglobin and pulse rate during both no motion and motion conditions, and for patients who are well or poorly perfused, using a range of compatible sensors. The device will produce visual and aural alarms if these parameters vary beyond preset limits

Assessment of non-clinical performance data for equivalence: See Section J

Assessment of clinical performance data for equivalence: See Section J

Biocompatibility: Not applicable

Sterilization: Not applicable

Standards and Guidances: See Section J



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

NOV 25 2003

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Penelope H. Greco  
Draeger Medical System, Incorporated  
16 Electronics Avenue  
Danvers, MA 01923

Re: K032537  
Trade/Device Name: Draeger Infinity MicroO2+  
Regulation Number: 870.2700  
Regulation Name: Oximeter  
Regulatory Class: II  
Product Code: DQA, DPZ  
Dated: November 14, 2003  
Received: November 17, 2003

Dear Ms. Greco:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

Page 2 – Ms. Penelope H. Greco

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



for

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

